HLX10 + carboplatin + etoposide

HLX10 + carboplatin + etoposide is a combination of three anticancer agents:\n- **HLX10** is a fully humanized anti-PD-1 monoclonal antibody (immunotherapy), developed by Shanghai Henlius Biotech, which enhances T-cell mediated immune response against tumors by blocking PD-1, a checkpoint regulator on T cells[1][2][3]. \n- **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and DNA damage in rapidly dividing cells, leading to apoptosis. \n- **Etoposide** is a topoisomerase II inhibitor, interfering with DNA synthesis and cell division by inducing DNA strand breaks.\nThis combination is under investigation (not approved) as a regimen for advanced/metastatic cancers, including non-small cell lung cancer, leveraging both immune checkpoint blockade and cytotoxic chemotherapy[1].